Aminoglycoside Antibiotic
Gentamicin Sulfate for Epidermolysis Bullosa
This trial will test if gentamicin can be used to treat Herlitz junctional epidermolysis bullosa (H-JEB), an incurable skin disease, by restoring laminin 332 assembly and improving wound closure.
Popular Filters
Trials for EB Patients
Mesenchymal Stromal Cells
Stem Cell Therapy for Epidermolysis Bullosa
This trial is testing a special cell therapy given through an IV to people with a severe genetic skin condition called RDEB. The therapy aims to help heal and grow new, healthy skin. Researchers are evaluating its safety and effectiveness. Previous tests have shown increased collagen expression and faster wound healing in patients with RDEB.
Antimicrobial Wound Cleansing Spray
Antimicrobial Wound Cleansing Spray for Epidermolysis Bullosa
This trial tests a special spray to clean and heal infected wounds in patients with a rare skin condition. The spray aims to reduce harmful bacteria, helping the wounds heal better.
Gene Therapy
FCX-007 for Epidermolysis Bullosa
This trial tests if FCX-007 can improve wound healing in people with RDEB, a condition causing persistent wounds. FCX-007 is injected into the skin to help it heal by providing missing elements. The study observes how treated wounds heal compared to other wounds in the same patients. FCX-007 is a gene therapy designed to deliver COL7A1 to the skin, aiming to restore collagen VII expression and improve wound healing in RDEB patients.
Trials With No Placebo
Antimicrobial Wound Cleansing Spray
Antimicrobial Wound Cleansing Spray for Epidermolysis Bullosa
This trial tests a special spray to clean and heal infected wounds in patients with a rare skin condition. The spray aims to reduce harmful bacteria, helping the wounds heal better.
Gene Therapy
FCX-007 for Epidermolysis Bullosa
This trial tests if FCX-007 can improve wound healing in people with RDEB, a condition causing persistent wounds. FCX-007 is injected into the skin to help it heal by providing missing elements. The study observes how treated wounds heal compared to other wounds in the same patients. FCX-007 is a gene therapy designed to deliver COL7A1 to the skin, aiming to restore collagen VII expression and improve wound healing in RDEB patients.
Small Molecule
Rigosertib for Skin Cancer in Dystrophic Epidermolysis Bullosa
This trial studies how rigosertib sodium, a drug taken orally or through IV, can help treat patients with a rare skin condition and advanced skin cancer who haven't responded to other treatments. The drug targets and kills cancer cells while leaving healthy cells alone. Rigosertib has shown potential as a therapeutic option for nonresectable cholangiocarcinoma, demonstrating antitumoral and radiosensitizing effects.
Frequently Asked Questions
Introduction to epidermolysis bullosa
What are the top hospitals conducting epidermolysis bullosa research?
When it comes to pushing the boundaries of medical progress in the field of epidermolysis bullosa (EB), several top hospitals are leading the way. In Los Angeles, the University of Southern California is at the forefront with three active clinical trials focused on this rare genetic condition that causes fragile and blister-prone skin. Since their first recorded trial in 2017, they have been dedicated to finding innovative treatments for EB. Meanwhile, in Chicago, at Ann & Robert H. Lurie Children's Hospital, researchers are currently conducting two active trials for EB and have shown commitment since their initial trial in 2012.
In Minneapolis, the Masonic Cancer Center and Medical Center is contributing to EB research by conducting one ongoing clinical trial—one step closer to finding effective therapies for patients suffering from this debilitating condition—since recording their inaugural trial set to start in 2023.Stanford University has also made significant contributions with its nine completed trials focusing on epidermolysis bullosa since initiating their first investigation backin 2019 based out of Redwood City vicinity.Their efforts continue now with an ongoing study aimed towards further advancements.Meanwhile,the University of Massachusetts Medical School has joined this fight by conducting two previous experiments before introducing a novel current project started off only last year
These hospitals' dedication and groundbreaking work highlight not just scientific innovation but also compassion towards those affected by this challenging condition worldwide.For individuals living with EB—a disorder characterized by painful blisters and wounds even from minor friction or trauma—these clinical trials represent rays of hope that could potentially alleviate symptoms or even lead to a cure.As these institutions continue embarking on new frontiers against epidermolysis bullosa,it is evident that through collaboration between researchers,pioneers,and patients;the possibilities for improving lives impacted by such diseases expand significantly
Which are the best cities for epidermolysis bullosa clinical trials?
When it comes to epidermolysis bullosa clinical trials, a few cities have emerged as leaders in research and development. Los Angeles, California is currently conducting 3 active trials focusing on treatments like Biweekly IV Gentamicin and Intravenous Gentamicin. Minneapolis, Minnesota and Worcester, Massachusetts both have 2 ongoing studies exploring therapies such as Verum and EB-101 Surgical application of RDEB wounds respectively. Furthermore, Chicago, Illinois and Stanford, California also boast 2 active trials each with their own unique investigational drugs. These cities provide individuals with epidermolysis bullosa access to cutting-edge clinical trials that hold promise for improved management of this challenging condition.
Which are the top treatments for epidermolysis bullosa being explored in clinical trials?
Exciting developments are underway in clinical trials exploring treatments for epidermolysis bullosa (EB). Leading the charge is EB-101, which involves the surgical application of RDEB wounds. With one active trial and a debut listing in 2023, it shows promising potential. Another contender making waves is APR-TD011, also with one active trial and first listed in 2023. Last but not least is ALLO-ASC-SHEET, presenting another avenue of exploration for EB treatment. It too has one active trial and entered the scene in 2023. These innovative approaches hold great promise for advancing the management and care of individuals affected by this challenging condition.
What are the most recent clinical trials for epidermolysis bullosa?
Recent clinical trials are bringing hope to those affected by epidermolysis bullosa, a challenging condition characterized by fragile skin. One notable study is investigating the efficacy of Verum, a potential treatment for this debilitating disease. In another trial, ALLO-ASC-SHEET shows promise as a therapy option in managing epidermolysis bullosa symptoms. Additionally, PTW-002 10 mg/g gel has demonstrated potential benefits in addressing the concerns associated with this condition. Another trial focuses on the surgical application of EB-101 for recessive dystrophic epidermolysis bullosa wounds. Finally, FCX-007 offers new prospects as it progresses through Phase 3 trials and aims to address the challenges faced by individuals with epidermolysis bullosa. These ongoing studies hold great promise for improving the lives of those living with this rare genetic disorder.
What epidermolysis bullosa clinical trials were recently completed?
Recently completed clinical trials for epidermolysis bullosa have made significant strides in advancing potential treatments for this debilitating condition. In December 2021, Phoenix Tissue Repair successfully completed a trial investigating the efficacy of PTR-01. Another notable trial was finished in May 2018 by Krystal Biotech, examining the topical application of beremagene geperpavec. Furthermore, Amryt Research Limited concluded their Oleogel-S10 study in March 2017 and the Masonic Cancer Center at the University of Minnesota wrapped up their bone marrow infusion trial in March 2016. These recent developments bring hope to individuals affected by epidermolysis bullosa and emphasize ongoing efforts to find effective therapeutic solutions for this challenging disease.